T. Rowe Price Investment Management, Inc. Nurix Therapeutics, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $166 Billion
- Q3 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 2,548,091 shares of NRIX stock, worth $50.9 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
2,548,091
Previous 2,189,192
16.39%
Holding current value
$50.9 Million
Previous $45.7 Million
25.32%
% of portfolio
0.03%
Previous 0.03%
Shares
4 transactions
Others Institutions Holding NRIX
# of Institutions
181Shares Held
68.1MCall Options Held
78KPut Options Held
53.8K-
Black Rock Inc. New York, NY6.82MShares$136 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.28MShares$85.5 Million6.28% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.01MShares$80.2 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY3.88MShares$77.6 Million0.93% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.87MShares$77.3 Million3.2% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $942M
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...